Phase I study of carboplatin, doxorubicin and weekly paclitaxel in patients with advanced ovarian carcinoma
Authors:
Open Access
- 1 April 2003
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 14 (4) , 638-642
Abstract
Background: Doxorubicin is an active compound in epithelial ovarian cancer (EOC), but adding it to carboplatin–paclitaxel causes toxicity. Toxicity can be reduced by weekly administration. We examined the tolerability of weekly paclitaxel in combination with carboplatin and doxorubicin. Patients and methods: Chemotherapy naïve patients with EOC were treated with doxorubicin (50 mg/m2 day 1), carboplatin (AUC 6 day 1) and paclitaxel (days 1, 8, 15, 21), 28-day cycle. Three patients were treated at each paclitaxel dose level, starting at 60, 75 and 90 mg/m2/week. If more than two patients in a cohort experienced dose-limiting toxicity (DLT) three more patients were treated at the dose level below. Results: Twelve patients with advanced EOC received a median of six cycles (range 2–6) of the three-drug combination. DLT occurred at dose level 3: prolonged grade 4 febrile neutropenia, 1 patient; grade 3 peripheral neuropathy, 1 patient. All six patients treated at dose level 2 experienced short-lived grade 4 neutropenia, which led to dose modifications resulting in an actual delivered dose of paclitaxel of 64 mg/m2/week. Eight out of 12 patients had measurable disease on CT scan: four obtained a partial remission; three had stable disease. Conclusions: The combination of carboplatin, doxorubicin and paclitaxel in patients with EOC is active and its main toxicity is myelosuppression. Dose intensity of paclitaxel can be maintained in a three-drug combination through weekly administration (65 mg/m2).Keywords
This publication has 15 references indexed in Scilit:
- Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in Stage III and IV ovarian carcinomaCancer, 2000
- Exploratory Phase III Study of Paclitaxel and Cisplatin Versus Paclitaxel and Carboplatin in Advanced Ovarian CancerJournal of Clinical Oncology, 2000
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI: Journal of the National Cancer Institute, 2000
- Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancyEuropean Journal of Cancer, 2000
- First-Line Chemotherapy With Epirubicin, Paclitaxel, and Carboplatin for Advanced Ovarian Cancer: A Phase I/II Study of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study GroupJournal of Clinical Oncology, 1999
- A Phase I Study of Paclitaxel, Doxorubicin, and Cisplatin in Patients with Previously Untreated Epithelial Ovarian CancerGynecologic Oncology, 1998
- A Phase I/II Study of Dose-Intense Paclitaxel with Cisplatin and Cyclophosphamide as Initial Therapy of Poor-Prognosis Advanced-Stage Epithelial Ovarian CancerGynecologic Oncology, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Impact of doxorubicin on survival in advanced ovarian cancer.Journal of Clinical Oncology, 1995
- Dose-Intense Taxol: High Response Rate in Patients With Platinum-Resistant Recurrent Ovarian CancerJNCI: Journal of the National Cancer Institute, 1994